Health Canada publishes new guidance on “significant change” for medical devices

Health Canada has released a new guidance document clarifying how manufacturers should interpret and assess a “significant change” to licensed medical devices.

The document is particularly relevant for manufacturers of Class III and IV devices, as it outlines when a modification requires a licence amendment application prior to implementation.

What is a “significant change”?

According to Health Canada, a significant change is any modification that could reasonably affect the safety or effectiveness of a device.

This includes changes related to:

• Design and performance

• Manufacturing processes or facilities

• Software

• Materials

• Labelling and intended use

If a change meets this threshold, manufacturers must obtain an amended licence before placing the modified device on the Canadian market.

Key principles introduced

The guidance provides a structured approach for assessing changes, including:

• Risk-based assessment: Manufacturers are expected to evaluate new or modified risks, including unintended consequences.

• “Four-corner principle”: Changes within the previously approved design range may be considered non-significant—provided performance remains predictable.

• Cumulative impact: Multiple minor changes can collectively become significant.

Detailed examples across change types

A notable strength of the guidance is the extensive use of practical examples, covering:

• Manufacturing changes (e.g., new facilities or equipment)

• Design modifications (e.g., new components, dimensions, or operating principles)

• Software updates (including AI/ML systems)

• Material changes (including biocompatibility considerations)

• Labelling updates (especially changes to intended use or patient population)

These examples help clarify borderline cases, which are often challenging for manufacturers.

Implications for manufacturers

This guidance has several practical consequences:

• Earlier regulatory assessment required
  Manufacturers must evaluate changes before implementation, not retrospectively.

• Stronger reliance on risk management
  Robust risk assessments (aligned with ISO 14971) are central to determining significance.

• Increased documentation expectations
  Even non-significant changes must be documented within the QMS and reported at licence renewal.

• Impact on lifecycle management
  Iterative changes—especially in software and combination systems—may trigger frequent amendment submissions.

Broader regulatory alignment

While specific to Canada, the concepts align closely with other frameworks such as:

• EU MDR expectations on significant changes and conformity

• MDCG guidance on substantial changes for legacy devices

This reinforces a global trend toward stricter control of post-market changes.

Smart MDR insight:

Manufacturers should treat this guidance as a decision-making tool, not just a regulatory reference. Embedding these principles into change control procedures will be key to avoiding delays, non-compliance, or unexpected regulatory submissions.

Read the full document below.